Press Announcements > FDA approves Odactra for house dust mite allergies

Press Announcements > FDA approves Odactra for house dust mite allergies

FDA approves Odactra for house dust mite allergies

03/01/2017 04:57 PM EST

The U.S. Food and Drug Administration today approved Odactra, the first allergen extract to be administered under the tongue (sublingually) to treat house dust mite (HDM)-induced nasal inflammation (allergic rhinitis), with or without eye inflammation (conjunctivitis), in people 18 through 65 years of age.